This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jamda.2020.07.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prostate artery embolization as an effective treatment for clinically significant prostate cancer‑related hemorrhage: A case report.
Exp Ther Med
February 2025
Department of Urology, Konstantopouleio-Patision General Hospital of Nea Ionia, 14233 Nea Ionia, Greece.
A 79-year old Caucasian male with metastatic hormone refractory prostate cancer and bilateral nephrostomy was admitted to the emergency department due to 4-day bloody urethral discharge, weakness and dizziness. The patient was treated with the luteinizing hormone-releasing hormone-antagonist and abiraterone acetate plus prednisone, dabigatran 150 mg bid (for atrial fibrillation and coronary heart disease) and 5-aminosalicylic acid for the management of mild ulcerative colitis. Imaging revealed bladder overdistention and blood analysis low levels of hematocrit (HCT) and hemoglobin (HGB) (HCT, 22%; HGB, 7.
View Article and Find Full Text PDFApplication of synchronous music reinforcement to increase walking speed: A novel approach for training intensity.
J Exp Anal Behav
November 2024
Department of Psychology, University of Manitoba, Winnipeg, MB, Canada.
Walking is a common and preferred form of exercise. Although there are current recommendations for walking volume (e.g.
View Article and Find Full Text PDFLong-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission.
Eur J Heart Fail
September 2024
National Heart & Lung Institute, Imperial College, London, UK.
Aims: In TRED-HF, 40% of patients with recovered dilated cardiomyopathy (DCM) relapsed in the short term after therapy withdrawal. This follow-up investigates the longer-term effects of therapy withdrawal.
Methods And Results: TRED-HF was a randomized trial investigating heart failure therapy withdrawal in patients with recovered DCM over 6 months.
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Nat Med
December 2024
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Article Synopsis
- * In a trial involving 1,372 participants, spironolactone did not show a significant reduction in cardiovascular incidents compared to usual care, with similar events occurring in both groups over three years.
- * Many participants discontinued spironolactone due to safety concerns, particularly related to decreases in kidney function and side effects, leading to the conclusion that it may not be a suitable treatment for this population.
Uterine artery pseudoaneurysm caused by hysteroscopic surgery: A case report.
World J Clin Cases
September 2024
Department of Obstetrics and Gynecology, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, Japan.
Background: We report a case of uterine artery pseudoaneurysm (UAP) occurrence during hysteroscopic endometrial polypectomy and its treatment uterine artery embolization (UAE).
Case Summary: A 48-year-old primigravid, primiparous patient was incidentally found to have an endometrial polyp during a health checkup, and underwent a hysteroscopic polypectomy at another hospital. Her cervix was dilated with a Laminken-R device.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!